Iovance Biotherapeutics, Inc. (FRA:2LB)

Iovance Biotherapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 26, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	761	2,178	1,882	944	2,634	5,564
Market Cap Growth	-70.64%	15.73%	99.45%	-64.17%	-52.67%	78.76%
Enterprise Value	548	1,871	1,627	682	2,190	4,989
Last Close Price	2.00	7.00	7.85	5.90	17.00	39.03
PS Ratio	3.57	13.75	1749.89	-	-	-
PB Ratio	1.27	3.18	3.56	2.02	4.82	10.37
P/TBV Ratio	2.14	5.27	5.86	2.02	4.82	10.37
EV/Sales Ratio	2.54	11.81	1512.80	-	-	-
Debt / Equity Ratio	0.08	0.08	0.13	0.17	0.12	0.08
Asset Turnover	0.26	0.19	0.00	-	-	-
Inventory Turnover	4.40	4.01	-	-	-	-
Quick Ratio	2.92	3.21	2.54	5.16	5.66	11.47
Current Ratio	3.41	3.74	2.79	5.24	5.70	11.59
Return on Equity (ROE)	-53.89%	-57.48%	-81.91%	-70.61%	-53.55%	-54.34%
Return on Assets (ROA)	-27.12%	-29.22%	-39.86%	-34.59%	-27.71%	-29.42%
Return on Capital (ROIC)	-31.99%	-34.57%	-46.22%	-39.01%	-30.57%	-32.14%
Return on Capital Employed (ROCE)	-52.80%	-50.20%	-68.70%	-69.70%	-49.80%	-36.70%
Earnings Yield	-44.51%	-16.50%	-21.34%	-39.25%	-11.43%	-3.81%
FCF Yield	-39.38%	-16.14%	-18.46%	-31.05%	-8.87%	-3.70%
Buyback Yield / Dilution	-19.46%	-23.28%	-47.64%	-3.82%	-10.92%	-11.23%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.